Universal Beteiligungs und Servicegesellschaft mbH Acquires 106,263 Shares of Guardant Health, Inc. $GH

Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 54.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 301,449 shares of the company’s stock after buying an additional 106,263 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.24% of Guardant Health worth $18,835,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Edgestream Partners L.P. lifted its position in Guardant Health by 147.3% during the second quarter. Edgestream Partners L.P. now owns 50,519 shares of the company’s stock valued at $2,629,000 after acquiring an additional 30,094 shares during the last quarter. State of Wyoming purchased a new position in Guardant Health in the second quarter worth $567,000. Yorktown Management & Research Co Inc acquired a new position in shares of Guardant Health during the second quarter worth $289,000. Federated Hermes Inc. lifted its holdings in shares of Guardant Health by 72.4% during the 2nd quarter. Federated Hermes Inc. now owns 1,465,438 shares of the company’s stock valued at $76,261,000 after purchasing an additional 615,429 shares during the last quarter. Finally, Calamos Advisors LLC acquired a new stake in shares of Guardant Health in the 3rd quarter worth $2,780,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Guardant Health Trading Down 2.2%

Shares of NASDAQ:GH opened at $114.75 on Friday. Guardant Health, Inc. has a twelve month low of $34.88 and a twelve month high of $120.74. The company has a market cap of $14.46 billion, a PE ratio of -35.75 and a beta of 1.58. The company’s 50 day moving average is $105.24 and its 200 day moving average is $77.45.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.09. The business’s revenue was up 38.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.88) EPS. Equities research analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Amirali Talasaz sold 100,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $105.05, for a total transaction of $10,505,000.00. Following the sale, the chief executive officer directly owned 168,223 shares of the company’s stock, valued at $17,671,826.15. This trade represents a 37.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Terilyn J. Monroe sold 8,571 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total value of $977,865.39. Following the completion of the transaction, the insider directly owned 20,990 shares of the company’s stock, valued at $2,394,749.10. The trade was a 28.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 445,123 shares of company stock valued at $46,600,702 in the last 90 days. 6.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GH. Barclays upped their target price on Guardant Health from $85.00 to $120.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Leerink Partners upped their price objective on shares of Guardant Health from $115.00 to $155.00 and gave the company an “outperform” rating in a report on Monday, December 15th. BTIG Research lifted their target price on shares of Guardant Health from $100.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. UBS Group boosted their target price on shares of Guardant Health from $80.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Finally, Mizuho set a $135.00 price target on shares of Guardant Health in a report on Friday, January 9th. Twenty-one analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $102.81.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.